Chemed Corporation (NYSE:CHE) Receives Average Rating of “Moderate Buy” from Brokerages

Chemed Corporation (NYSE:CHE) has been given an average rating of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $578.50.

CHE has been the topic of a number of recent research reports. Oppenheimer reduced their price target on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and lifted their price target for the company from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada reduced their target price on shares of Chemed from $640.00 to $589.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st.

Chemed Stock Up 2.2%

Shares of CHE stock opened at $440.80 on Tuesday. The stock has a market cap of $6.42 billion, a price-to-earnings ratio of 23.31, a price-to-earnings-growth ratio of 2.69 and a beta of 0.43. Chemed has a fifty-two week low of $408.42 and a fifty-two week high of $623.60. The firm’s 50 day moving average price is $447.38 and its two-hundred day moving average price is $491.17.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The business had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. Chemed had a net margin of 11.02% and a return on equity of 25.89%. The company’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm earned $5.64 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, equities analysts forecast that Chemed will post 21.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Patrick P. Grace sold 150 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total transaction of $69,508.50. Following the transaction, the director directly owned 3,397 shares of the company’s stock, valued at approximately $1,574,135.83. The trade was a 4.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the transaction, the chief executive officer directly owned 96,197 shares in the company, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 3.29% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Creekmur Asset Management LLC bought a new stake in shares of Chemed in the second quarter worth $28,000. HM Payson & Co. bought a new stake in shares of Chemed in the first quarter worth $30,000. SVB Wealth LLC bought a new stake in shares of Chemed in the first quarter worth $30,000. First Horizon Corp bought a new stake in shares of Chemed in the third quarter worth $31,000. Finally, WPG Advisers LLC bought a new stake in shares of Chemed in the first quarter worth $32,000. 95.85% of the stock is owned by institutional investors and hedge funds.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.